Page 1253 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1239

Rifampin Routes of exposure, 1005 nature of, 512
buspirone affected by, 385b Royal jelly, 1133t psychosocial and cognitive remediation
drug interactions of, 1172t Rubella, immune globulin for, 1181t for, 523
leprosy treated with, 851, 851t Rufinamide, 430, 433t, 436t serotonin hypothesis of, 512
tuberculosis treated with, 842, 843t, Rytary, 495 Sclerostin, 774f
845, 851t Scopolamine, 125, 130t, 135t, 284. See also
Rifapentine, 843t, 849 S Muscarinic receptor blockers
Right to prescribe, 1151, 1152b Sabal serrulata, 1141 action of, 127, 128f
Rilonacept, 657–658, 994 Sacubitril, 220, 222, 225t, 310 antiemetic properties of, 1106
Rilpivirine, 873, 878–879 S-adenosyl-l-methionine (SAMe), 63, 64t Scorpion antivenom, 991
Riluzole, 487 Safety testing, preclinical, 13, 13t Screening, drug, 12–13
Rimantadine, 892 Safinamide, 508t Sebelipase alfa, 631
Rimonabant Salbutamol, 154t, 351. See Albuterol Secobarbital, 383f, 393t. See also
cannabinoid dependence treated with, Salicylates, 645, 645t, 646f Barbiturates
588, 589t drug interactions of, 1172t Secondary amine, 9, 60t
obesity treated with, 289b in neonates, 1053t Second messengers, 32–34
Riociguat, 313b in OTC agents, 1129t cAMP, 32, 34, 34f
Risedronate poisoning management for, 1042–1043 cGMP, 34, 343f
on bone homeostasis, 779–781 Salicylic acid, 1082 diffusible, in central nervous system,
bone metastases treated with, 789t Salicylism, 1082 369f, 370
hypercalcemia treated with, 789t Saline diuresis, 782 phosphoinositides and calcium, 32–34, 34f
osteoporosis treated with, 780b, 786, 789t Salivary glands, 148 Secukinumab, 656, 994
Paget’s disease of bone treated with, 789 Salmeterol Sedation, 441b. See also Anesthetics, general
Risk, 1005 asthma treated with, 351, 362t conscious, 441b
Risk Evaluation and Mitigation Strategy structure of, 350f deep, 441b
(REMS), 1153 Salmon calcitonin, 778 Sedative-hypnotic drugs, 381–394, 394t
Risperidone, 514f, 515, 520t, 529t Salt restriction, dietary, 221–222 actions of, 381
Ritanserin, 292 Salts, nonabsorbable, 1098 adverse effects of, 392
Ritonavir, 872t, 881 Sampatrilat, 310, 317t buspirone, 288–289, 383, 385b, 394t
Rituximab, 993 Sanitization, 898t chemical classification of
chronic lymphocytic leukemia treated Saquinavir, 872t, 881–882 barbiturates, 382, 383f
with, 970 Saralasin, 38 benzodiazepines, 381, 382f
rheumatoid arthritis treated with, 652 Sarcomere, cardiac muscle, 213, 214f newer hypnotics, 382–383, 383f
2+
Rivaroxaban, 617 Sarcoplasmic endoplasmic reticulum Ca - clinical pharmacology of, 390t, 390–393
Rivastigmine, 1063 ATPase (SERCA) transporter, 213 anxiety states, 390–391
Rizatriptan, 291t, 296t Sarcoserine, 515 delirium tremens, 391
Rocuronium. See also Neuromuscular Sargramostim, 602, 602t, 606t dosages, 394t
blocking drugs Sarin, 116f, 122t. See also Organophos- other therapeutic uses, 391–392
properties of, 478t, 479t, 489t phate cholinesterase inhibitors sleep problems, 391
structure of, 477f Sassafras, 1133t withdrawal from physiologic
Roflumilast, 352, 361, 362t Saw palmetto (Serenoa repens, Sabal dependence, 393
Romidepsin, 1085 serrulata), 1141 dose-response curves for, 381, 382f
Romiplostim, 602t, 604–605, 606t Saxagliptin, 763, 769t in elderly, 1061
Romosozumab, 775, 780b Scavenger receptors, 626 hypnotic actions, 381
Ropinirole. See also Dopamine receptor Schild equation, 24 lethal dose of, 392
agonists Schistosoma haematobium, 943 overdose of, 392
Parkinson’s disease treated with, 499, 508t Schistosoma mansoni, 943–944 pharmacodynamics of, 386–389
restless legs syndrome treated with, 507, Schistosomiasis, 944 benzodiazepine binding site ligands in,
508t Schizoaffective disorders 387–388
Ropivacaine, 460t, 461b, 462, 471, 472t. antipsychotics for, 519 chloride channel GABA receptor
See also Anesthetics, local lithium for, 526 complex versatility in, 386, 387f,
Rosiglitazone, 760, 768t Schizonticides, 917–918, 918f 388b
Rosuvastatin, 83, 632–634, 639t Schizophrenia. See also Antipsychotic agents GABA A receptor molecular pharma-
Rotavirus vaccine, 1177t antipsychotics for, 518 cology in, 386, 387f
Rotenone, 1012, 1013f case study of, 511, 531 GABA receptor heterogeneity and
Rotigotine, 499. See also Dopamine dopamine hypothesis of, 512–513 pharmacologic selectivity in, 387b
receptor agonists glutamate hypothesis of, 513 neuropharmacology in, 386–387
Routes of administration, 47t, 48 lithium for, 526 organ level effects in, 388–389